01 March 1999
Molecular and therapeutical aspects of the blood platelet receptors antagonists
Marcin Różalski, Magdalena Boncler, Bogusława Więcławska, Cezary WatałaMed Sci Monit 1999; 5(2): RA357-375 :: ID: 505175
Abstract
Many new, potent, antiplatelet agents belonging to the group of platelet receptors antagonists became recently available for clinical evaluation and intervention. Amongst platelet inhibitors of a newer generation including inhibitors of platelet adhesion, inhibitors of specific platelet agonist-receptor interactions (antithrombins, fibrinogen receptor antagonists, thromboxane A2, receptor antagonists, ADP receptor blockers like ticlopidine and clopidogrel, or inhibitors of thromboxane synthase and arachidonic acid metabolism), only the antagonists of platelet receptors have been demonstrated to allow more global interruption of both the initial and final steps of platelet-dependent prothrombotic events. Due to the considerable progress in the development of novel agents aimed to reducing platelet-derived thrombosis, various antiplatelet drugs have been invented, which are rationally based on interrupting specific sites in the sequence of platelet activation, adhesion and aggregation. The antagonists of platelet receptors focus considerable attention, because they are able to directly interfere with the interactions between blood platelets and their ligands. The common feature of these agents is that they are designed to interrupt platelet response at the very initial stage of platelet activation - when the 'outside-in receptor-mediated' triggers signal transduction in platelet cytoplasm. In that sense, the antagonists of platelet receptors are believed to represent quite a new approach to the treatment of platelet thrombosis.
Keywords: antiplatelet drugs, peptidomimetics, monoclonal antibodies, RGD-derived ligands, peptidomimetics
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952